REFERENCES
1. Chung KF, Adcock IM. Precision medicine for the discovery of
treatable mechanisms in severe asthma. Allergy.2019;74(9):1649-1659.
2. Agache I, Akdis CA. Precision medicine and phenotypes, endotypes,
genotypes, regiotypes, and theratypes of allergic diseases. J Clin
Invest. 2019;129(4):1493-1503.
3. Olafsdottir TA, Theodors F, Bjarnadottir K, et al. Eighty-eight
variants highlight the role of T cell regulation and airway remodeling
in asthma pathogenesis. Nat Commun. 2020;11(1):393.
4. Guo Y, Moon JY, Laurie CC, et al. Genetic predisposition to obesity
is associated with asthma in US Hispanics/Latinos: Results from the
Hispanic Community Health Study/Study of Latinos. Allergy.2018;73(7):1547-1550.
5. D’Amato G, Annesi-Maesano I, Cecchi L, D’Amato M. Latest news on
relationship between thunderstorms and respiratory allergy, severe
asthma, and deaths for asthma. Allergy. 2019;74(1):9-11.
6. Kim J, Kim YC, Ham J, et al. The effect of air pollutants on airway
innate immune cells in patients with asthma. Allergy. 2020.
7. Celebi Sözener Z, Cevhertas L, Nadeau K, Akdis M, Akdis CA.
Environmental factors in epithelial barrier dysfunction. J Allergy
Clin Immunol. 2020;145(6):1517-1528.
8. Papi A, Brightling C, Pedersen SE, Reddel HK. Asthma. Lancet.2018;391(10122):783-800.
9. Borna E, Nwaru BI, Bjerg A, et al. Changes in the prevalence of
asthma and respiratory symptoms in western Sweden between 2008 and 2016.Allergy. 2019;74(9):1703-1715.
10. Branco PTBS, Alvim-Ferraz MCM, Martins FG, Ferraz C, Vaz LG, Sousa
SIV. Asthma in urban and rural pre- and primary schoolchildren according
to the latest GINA definition. Allergy. 2020;75(7):1771-1776.
11. Liu X, Andersen SL, Olsen J, et al. Maternal hypothyroidism in the
perinatal period and childhood asthma in the offspring. Allergy.2018;73(4):932-939.
12. Odling M, Andersson N, Ekstrom S, Melen E, Bergstrom A, Kull I.
Characterization of asthma in the adolescent population. Allergy.2018;73(8):1744-1746.
13. Keller T, Hohmann C, Standl M, et al. The sex-shift in single
disease and multimorbid asthma and rhinitis during puberty - a study by
MeDALL. Allergy. 2018;73(3):602-614.
14. Farzan N, Vijverberg SJ, Hernandez-Pacheco N, et al. 17q21 variant
increases the risk of exacerbations in asthmatic children despite
inhaled corticosteroids use. Allergy. 2018;73(10):2083-2088.
15. Gorlanova O, Illi S, Toncheva AA, et al. Protective effects of
breastfeeding on respiratory symptoms in infants with 17q21 asthma risk
variants. Allergy. 2018;73(12):2388-2392.
16. Hur GY, Pham A, Miller M, et al. ORMDL3 but not neighboring 17q21
gene LRRC3C is expressed in human lungs and lung cells of asthmatics.Allergy. 2020.
17. Agusti A, Faner R. Lung function trajectories in health and disease.Lancet Respir Med. 2019;7(4):358-364.
18. Krautenbacher N, Flach N, Bock A, et al. A strategy for
high-dimensional multivariable analysis classifies childhood asthma
phenotypes from genetic, immunological, and environmental factors.Allergy. 2019;74(7):1364-1373.
19. Dijk FN, Vijverberg SJ, Hernandez-Pacheco N, et al. IL1RL1 gene
variations are associated with asthma exacerbations in children and
adolescents using inhaled corticosteroids. Allergy.2020;75(4):984-989.
20. Agache I, Miller R, Gern JE, et al. Emerging concepts and challenges
in implementing the exposome paradigm in allergic diseases and asthma: a
Practall document. Allergy. 2019;74(3):449-463.
21. Yang SI, Lee SY, Kim HB, et al. Prenatal particulate matter affects
new asthma via airway hyperresponsiveness in schoolchildren.Allergy. 2019;74(4):675-684.
22. Paciencia I, Cavaleiro Rufo J, Silva D, et al. Exposure to indoor
endocrine-disrupting chemicals and childhood asthma and obesity.Allergy. 2019;74(7):1277-1291.
23. Brandt EB, Bolcas PE, Ruff BP, Khurana Hershey GK. IL33 contributes
to diesel pollution-mediated increase in experimental asthma severity.Allergy. 2020.
24. Agache I, Annesi-Maesano I, Bonertz A, et al. Prioritizing research
challenges and funding for allergy and asthma and the need for
translational research-The European Strategic Forum on Allergic
Diseases. Allergy. 2019;74(11):2064-2076.
25. Weng CM, Wang CH, Lee MJ, et al. Aryl hydrocarbon receptor
activation by diesel exhaust particles mediates epithelium-derived
cytokines expression in severe allergic asthma. Allergy.2018;73(11):2192-2204.
26. Wang E, Liu X, Tu W, et al. Benzo(a)pyrene facilitates
dermatophagoides group 1 (Der f 1)-induced epithelial cytokine release
through aryl hydrocarbon receptor in asthma. Allergy.2019;74(9):1675-1690.
27. Gao Z, Fu WY, Sun Y, et al. Artemisia pollen allergy in China:
Component-resolved diagnosis reveals allergic asthma patients have
significant multiple allergen sensitization. Allergy.2019;74(2):284-293.
28. Hernández-Ramírez G, Pazos-Castro D, Gómez Torrijos E, et al. Group
1 allergens, transported by mold spores, induce asthma exacerbation in a
mouse model. Allergy. 2020.
29. Watai K, Fukutomi Y, Hayashi H, et al. De novo sensitization to
Aspergillus fumigatus in adult asthma over a 10-year observation period.Allergy. 2018;73(12):2385-2388.
30. Sullivan A, Hunt EB, Ward C, et al. The presence of Aspergillus
fumigatus in asthmatic airways is not clearly related to clinical
disease severity. Allergy. 2020;75(5):1146-1154.
31. Hew M, Lee J, Susanto NH, et al. The 2016 Melbourne thunderstorm
asthma epidemic: Risk factors for severe attacks requiring hospital
admission. Allergy. 2019;74(1):122-130.
32. Hew M, Lee J, Varese N, et al. Epidemic thunderstorm asthma
susceptibility from sensitization to ryegrass (Lolium perenne) pollen
and major allergen Lol p 5. Allergy. 2020.
33. Erbas B, Jazayeri M, Lambert KA, et al. Outdoor pollen is a trigger
of child and adolescent asthma emergency department presentations: A
systematic review and meta-analysis. Allergy.2018;73(8):1632-1641.
34. Kim SY, Sim S, Choi HG. Active and passive smoking impacts on asthma
with quantitative and temporal relations: A Korean Community Health
Survey. Sci Rep. 2018;8(1):8614.
35. McAlinden KD, Naidu V, Sohal SS, Sharma P. In utero Exposure to
Nicotine Containing Electronic Cigarettes Increases the Risk of Allergic
Asthma in Female Offspring. Am J Physiol Lung Cell Mol Physiol.2020.
36. Eddy RL, Serajeddini H, Knipping D, et al. Pulmonary Functional MRI
and CT in a Survivor of Bronchiolitis and Respiratory Failure Caused by
e-Cigarette Use. Chest. 2020.
37. Adkins SH, Anderson KN, Goodman AB, et al. Demographics, Substance
Use Behaviors, and Clinical Characteristics of Adolescents With
e-Cigarette, or Vaping, Product Use-Associated Lung Injury (EVALI) in
the United States in 2019. JAMA Pediatr. 2020:e200756.
38. Werner AK, Koumans EH, Chatham-Stephens K, et al. Hospitalizations
and Deaths Associated with EVALI. N Engl J Med.2020;382(17):1589-1598.
39. Chung SJ, Kim BK, Oh JH, et al. Novel tobacco products including
electronic cigarette and heated tobacco products increase risk of
allergic rhinitis and asthma in adolescents: Analysis of Korean youth
survey. Allergy. 2020;75(7):1640-1648.
40. Venter C, Meyer RW, Nwaru BI, et al. EAACI position paper: Influence
of dietary fatty acids on asthma, food allergy, and atopic dermatitis.Allergy. 2019;74(8):1429-1444.
41. Venter C, Greenhawt M, Meyer RW, et al. EAACI position paper on diet
diversity in pregnancy, infancy and childhood: Novel concepts and
implications for studies in allergy and asthma. Allergy.2020;75(3):497-523.
42. Kang SY, Song WJ, Kim MH, et al. Dietary assessment and the
development of asthma in Korean adolescents and adults. Allergy.2018;73(11):2254-2256.
43. Comberiati P, Peroni DG. Vitamin D supplementation in pregnancy does
not prevent school-age asthma. Allergy. 2020.
44. Litonjua AA, Carey VJ, Laranjo N, et al. Six-Year Follow-up of a
Trial of Antenatal Vitamin D for Asthma Reduction. N Engl J Med.2020;382(6):525-533.
45. Hennessy A, Hourihane JO, Malvisi L, et al. Antenatal vitamin D
exposure and childhood eczema, food allergy, asthma and allergic
rhinitis at 2 and 5 years of age in the atopic disease-specific Cork
BASELINE Birth Cohort Study. Allergy. 2018;73(11):2182-2191.
46. Tomita Y, Fukutomi Y, Irie M, et al. Acid-suppressive medication as
a possible risk factor for late-onset asthma. Allergy.2020;75(5):1247-1250.
47. Barcik W, Boutin RCT, Sokolowska M, Finlay BB. The Role of Lung and
Gut Microbiota in the Pathology of Asthma. Immunity.2020;52(2):241-255.
48. Sbihi H, Boutin RC, Cutler C, Suen M, Finlay BB, Turvey SE. Thinking
bigger: How early-life environmental exposures shape the gut microbiome
and influence the development of asthma and allergic disease.Allergy. 2019;74(11):2103-2115.
49. Walter J, O’Mahony L. The importance of social networks-An
ecological and evolutionary framework to explain the role of microbes in
the aetiology of allergy and asthma. Allergy.2019;74(11):2248-2251.
50. Stokholm J, Blaser MJ, Thorsen J, et al. Maturation of the gut
microbiome and risk of asthma in childhood. Nat Commun.2018;9(1):141.
51. Bannier MAGE, van Best N, Bervoets L, et al. Gut microbiota in
wheezing preschool children and the association with childhood asthma.Allergy. 2020;75(6):1473-1476.
52. Lee JJ, Kim SH, Lee MJ, et al. Different upper airway microbiome and
their functional genes associated with asthma in young adults and
elderly individuals. Allergy. 2019;74(4):709-719.
53. Kim BS, Lee E, Lee MJ, et al. Different functional genes of upper
airway microbiome associated with natural course of childhood asthma.Allergy. 2018;73(3):644-652.
54. Spacova I, Petrova MI, Fremau A, et al. Intranasal administration of
probiotic Lactobacillus rhamnosus GG prevents birch pollen-induced
allergic asthma in a murine model. Allergy. 2019;74(1):100-110.
55. Roßberg S, Keller T, Icke K, et al. Orally applied bacterial lysate
in infants at risk for atopy does not prevent atopic dermatitis,
allergic rhinitis, asthma or allergic sensitization at school age:
Follow-up of a randomized trial. Allergy. 2020.
56. Alhasan MM, Cait AM, Heimesaat MM, et al. Antibiotic use during
pregnancy increases offspring asthma severity in a dose-dependent
manner. Allergy. 2020.
57. Eguiluz-Gracia I, Mathioudakis AG, Bartel S, et al. The need for
clean air: The way air pollution and climate change affect allergic
rhinitis and asthma. Allergy. 2020.
58. Rahimi RA, Nepal K, Cetinbas M, Sadreyev RI, Luster AD. Distinct
functions of tissue-resident and circulating memory Th2 cells in
allergic airway disease. J Exp Med. 2020;217(9).
59. Vieira Braga FA, Kar G, Berg M, et al. A cellular census of human
lungs identifies novel cell states in health and in asthma. Nat
Med. 2019;25(7):1153-1163.
60. Asayama K, Kobayashi T, D’Alessandro-Gabazza CN, et al. Protein S
protects against allergic bronchial asthma by modulating Th1/Th2
balance. Allergy. 2020.
61. Bolcas PE, Brandt EB, Ruff BP, Kalra M, Khurana Hershey GK.
Cysteamine prevents asthma development and reduces airway
hyperresponsiveness in experimental asthma. Allergy. 2020.
62. Lu Y, Kared H, Tan SW, et al. Dynamics of helper CD4 T cells during
acute and stable allergic asthma. Mucosal Immunol.2018;11(6):1640-1652.
63. Khumalo J, Kirstein F, Scibiorek M, Hadebe S, Brombacher F.
Therapeutic and prophylactic deletion of IL-4Ra-signaling ameliorates
established ovalbumin induced allergic asthma. Allergy.2020;75(6):1347-1360.
64. Ro M, Lee AJ, Kim JH. 5-/12-Lipoxygenase-linked cascade contributes
to the IL-33-induced synthesis of IL-13 in mast cells, thus promoting
asthma development. Allergy. 2018;73(2):350-360.
65. Lv J, Xiong Y, Li W, et al. IL-37 inhibits IL-4/IL-13-induced CCL11
production and lung eosinophilia in murine allergic asthma.Allergy. 2018;73(8):1642-1652.
66. Russkamp D, Aguilar-Pimentel A, Alessandrini F, et al. IL-4 receptor
α blockade prevents sensitization and alters acute and long-lasting
effects of allergen-specific immunotherapy of murine allergic asthma.Allergy. 2019;74(8):1549-1560.
67. Hong JY, Kim M, Sol IS, et al. Chitotriosidase inhibits allergic
asthmatic airways via regulation of TGF-β expression and Foxp3.Allergy. 2018;73(8):1686-1699.
68. Sze E, Bhalla A, Nair P. Mechanisms and therapeutic strategies for
non-T2 asthma. Allergy. 2020;75(2):311-325.
69. Worth L, Michel S, Gaertner VD, Kabesch M, Schieck M. Asthma- and
IgE-associated polymorphisms affect expression of TH 17 genes.Allergy. 2018;73(6):1342-1347.
70. Ro M, Kwon SY, Kim JH. Leukotriene B4 receptors mediate the
production of IL-17, thus contributing to neutrophil-dominant asthmatic
airway inflammation. Allergy. 2019;74(9):1797-1799.
71. Ekstedt S, Stenberg H, Tufvesson E, et al. The potential role of
CD16(high) CD62L(dim) neutrophils in the allergic asthma.Allergy. 2019;74(11):2265-2268.
72. Brown GC, Vilalta A, Fricker M. Phagoptosis - Cell Death By
Phagocytosis - Plays Central Roles in Physiology, Host Defense and
Pathology. Current molecular medicine. 2015;15(9):842–851.
73. Ekstedt S, Tufvesson E, Bjermer L, Kumlien Georén S, Cardell LO. A
new role for ”eat me” and ”don’t eat me” markers on neutrophils in
asthmatic airway inflammation. Allergy. 2020;75(6):1510–1512.
74. Guan Q, Yang B, Warrington RJ, et al. Myeloid-derived suppressor
cells: Roles and relations with Th2, Th17, and Treg cells in asthma.Allergy. 2019;74(11):2233-2237.
75. Wirz OF, Globinska A, Ochsner U, et al. Comparison of regulatory B
cells in asthma and allergic rhinitis. Allergy.2019;74(4):815-818.
76. Brightling CE, Brusselle G, Altman P. The impact of the
prostaglandin D2 receptor 2 and its downstream effects on the
pathophysiology of asthma. Allergy. 2020;75(4):761-768.
77. Moon HG, Kim SJ, Lee MK, et al. Colony-stimulating factor 1 and its
receptor are new potential therapeutic targets for allergic asthma.Allergy. 2020;75(2):357-369.
78. Kim S-H, Jung H-W, Kim M, et al. Ceramide/sphingosine-1-phosphate
imbalance is associated with distinct inflammatory phenotypes of
uncontrolled asthma. Allergy. 2020.
79. Choi Y, Kim M, Kim SJ, Yoo H-J, Kim S-H, Park H-S. Metabolic shift
favoring C18:0 ceramide accumulation in obese asthma. Allergy.2020.
80. Felix MMR, Kuschnir FC. Arginase inhibitors: An alternative in
treatment of obese asthma? Allergy. 2020;75(6):1525–1526.
81. Meurs H, Zaagsma J, Maarsingh H, van Duin M. Recent Patents in
Allergy/Immunology: Use of arginase inhibitors in the treatment of
asthma and allergic rhinitis. Allergy. 2019;74(6):1206–1208.
82. Meurs H, Zaagsma J, Maarsingh H, van Duin M. Reply to: ”Arginase
inhibitors: An alternative in treatment of obese asthma?”.Allergy. 2020;75(6):1527–1528.
83. Ferreira DS, Carvalho-Pinto RM, Gregorio MG, et al. Airway pathology
in severe asthma is related to airflow obstruction but not symptom
control. Allergy. 2018;73(3):635-643.
84. Asaduzzaman M, Davidson C, Nahirney D, Fiteih Y, Puttagunta L,
Vliagoftis H. Proteinase-activated receptor-2 blockade inhibits changes
seen in a chronic murine asthma model. Allergy.2018;73(2):416-420.
85. Altman MC, Gill MA, Whalen E, et al. Transcriptome networks identify
mechanisms of viral and nonviral asthma exacerbations in children.Nat Immunol. 2019;20(5):637-651.
86. Hasegawa K, Hoptay CE, Harmon B, et al. Association of type 2
cytokines in severe rhinovirus bronchiolitis during infancy with risk of
developing asthma: A multicenter prospective study. Allergy.2019;74(7):1374-1377.
87. Lund RJ, Osmala M, Malonzo M, et al. Atopic asthma after
rhinovirus-induced wheezing is associated with DNA methylation change in
the SMAD3 gene promoter. Allergy. 2018;73(8):1735-1740.
88. Schuler CF, Malinczak C-A, Best SKK, et al. Inhibition of uric acid
or IL-1β ameliorates respiratory syncytial virus immunopathology and
development of asthma. Allergy. 2020.
89. Törmänen S, Lauhkonen E, Riikonen R, et al. Risk factors for asthma
after infant bronchiolitis. Allergy. 2018;73(4):916-922.
90. Schwarze J, Openshaw P, Jha A, et al. Influenza burden, prevention,
and treatment in asthma-A scoping review by the EAACI Influenza in
asthma task force. Allergy. 2018;73(6):1151-1181.
91. Yu QN, Guo YB, Li X, et al. ILC2 frequency and activity are
inhibited by glucocorticoid treatment via STAT pathway in patients with
asthma. Allergy. 2018;73(9):1860-1870.
92. Milara J, Morell A, de Diego A, Artigues E, Morcillo E, Cortijo J.
Mucin 1 deficiency mediates corticosteroid insensitivity in asthma.Allergy. 2019;74(1):111-121.
93. Bartel S, La Grutta S, Cilluffo G, et al. Human airway epithelial
extracellular vesicle miRNA signature is altered upon asthma
development. Allergy. 2020;75(2):346-356.
94. Suojalehto H, Lindstrom I, Wolff H, Puustinen A. Nasal protein
profiles in work-related asthma caused by different exposures.Allergy. 2018;73(3):653-663.
95. Uwadiae FI, Pyle CJ, Walker SA, Lloyd CM, Harker JA. Targeting the
ICOS/ICOS-L pathway in a mouse model of established allergic asthma
disrupts T follicular helper cell responses and ameliorates disease.Allergy. 2019;74(4):650-662.
96. Bateman ED, Reddel HK, van Zyl-Smit RN, Agusti A. The asthma-COPD
overlap syndrome: towards a revised taxonomy of chronic airways
diseases? Lancet Respir Med. 2015;3(9):719-728.
97. Wang YC, Jaakkola MS, Lajunen TK, Lai CH, Jaakkola JJK. Asthma-COPD
Overlap Syndrome among subjects with newly diagnosed adult-onset asthma.Allergy. 2018;73(7):1554-1557.
98. Campo P, Eguiluz-Gracia I, Plaza-Seron MC, et al. Bronchial asthma
triggered by house dust mites in patients with local allergic rhinitis.Allergy. 2019;74(8):1502-1510.
99. Toppila-Salmi S, Chanoine S, Karjalainen J, Pekkanen J, Bousquet J,
Siroux V. Risk of adult-onset asthma increases with the number of
allergic multimorbidities and decreases with age. Allergy.2019;74(12):2406-2416.
100. Samitas K, Carter A, Kariyawasam HH, Xanthou G. Upper and lower
airway remodelling mechanisms in asthma, allergic rhinitis and chronic
rhinosinusitis: The one airway concept revisited. Allergy.2018;73(5):993-1002.
101. Sharma N, Akkoyunlu M, Rabin RL. Macrophages-common culprit in
obesity and asthma. Allergy. 2018;73(6):1196-1205.
102. Chen YC, Fan HY, Yang C, Lee YL. Early pubertal maturation and risk
of childhood asthma: A Mendelian randomization and longitudinal study.Allergy. 2020;75(4):892-900.
103. Skaaby T, Taylor AE, Thuesen BH, et al. Estimating the causal
effect of body mass index on hay fever, asthma and lung function using
Mendelian randomization. Allergy. 2018;73(1):153-164.
104. Tay TR, Hew M. Comorbid ”treatable traits” in difficult asthma:
Current evidence and clinical evaluation. Allergy.2018;73(7):1369-1382.
105. Fokkens WJ, Lund V, Bachert C, et al. EUFOREA consensus on
biologics for CRSwNP with or without asthma. Allergy.2019;74(12):2312-2319.
106. Li Y, Jiang Q, Ji Y, Cao C. Anxiety and depression may associate
with poorer control and quality of life in adults with asthma.Allergy. 2020;75(7):1759-1762.
107. Lemonnier N, Melén E, Jiang Y, et al. A novel whole blood gene
expression signature for asthma, dermatitis, and rhinitis multimorbidity
in children and adolescents. Allergy. 2020.
108. Siroux V, Ballardini N, Soler M, et al. The asthma-rhinitis
multimorbidity is associated with IgE polysensitization in adolescents
and adults. Allergy. 2018;73(7):1447-1458.
109. Lemmetyinen RE, Karjalainen JV, But A, et al. Higher mortality of
adults with asthma: A 15-year follow-up of a population-based cohort.Allergy. 2018;73(7):1479-1488.
110. Postma DS, Brightling C, Baldi S, et al. Exploring the relevance
and extent of small airways dysfunction in asthma (ATLANTIS): baseline
data from a prospective cohort study. Lancet Respir Med.2019;7(5):402-416.
111. Shirai T, Akamatsu T, Hirai K, et al. Oscillometry improves earlier
than spirometry after benralizumab initiation in severe asthma.Allergy. 2020.
112. Dunn RM, Busse PJ, Wechsler ME. Asthma in the elderly and
late-onset adult asthma. Allergy. 2018;73(2):284-294.
113. Kowalski ML, Agache I, Bavbek S, et al. Diagnosis and management of
NSAID-Exacerbated Respiratory Disease (N-ERD)-a EAACI position paper.Allergy. 2019;74(1):28-39.
114. Diamant Z, Vijverberg S, Alving K, et al. Toward clinically
applicable biomarkers for asthma: An EAACI position paper.Allergy. 2019;74(10):1835-1851.
115. Celejewska-Wójcik N, Wójcik K, Ignacak-Popiel M, et al.
Subphenotypes of nonsteroidal antiinflammatory disease-exacerbated
respiratory disease identified by latent class analysis. Allergy.2020;75(4):831-840.
116. Mastalerz L, Tyrak KE, Ignacak M, et al. Prostaglandin E2 decrease
in induced sputum of hypersensitive asthmatics during oral challenge
with aspirin. Allergy. 2019;74(5):922-932.
117. Chen LC, Tseng HM, Kuo ML, et al. A composite of exhaled LTB4 ,
LXA4 , FeNO, and FEV1 as an ”asthma classification ratio” characterizes
childhood asthma. Allergy. 2018;73(3):627-634.
118. Tanaka H, Nakatani E, Fukutomi Y, et al. Identification of patterns
of factors preceding severe or life-threatening asthma exacerbations in
a nationwide study. Allergy. 2018;73(5):1110-1118.
119. Jutel M, Brüggenjürgen B, Richter H, Vogelberg C. Real-world
evidence of subcutaneous allergoid immunotherapy in house dust
mite-induced allergic rhinitis and asthma. Allergy. 2020.
120. Suarthana E, Taghiakbari M, Saha-Chaudhuri P, et al. The validity
of the Canadian clinical scores for occupational asthma in European
populations. Allergy. 2020.
121. Vandenplas O, Godet J, Hurdubaea L, et al. Are high- and
low-molecular-weight sensitizing agents associated with different
clinical phenotypes of occupational asthma? Allergy.2019;74(2):261-272.
122. Beretta C, Rifflart C, Evrard G, Jamart J, Thimpont J, Vandenplas
O. Assessment of eosinophilic airway inflammation as a contribution to
the diagnosis of occupational asthma. Allergy.2018;73(1):206-213.
123. Eguiluz-Gracia I, Tay TR, Hew M, et al. Recent developments and
highlights in biomarkers in allergic diseases and asthma.Allergy. 2018;73(12):2290-2305.
124. Tan HT, Hagner S, Ruchti F, et al. Tight junction, mucin, and
inflammasome-related molecules are differentially expressed in
eosinophilic, mixed, and neutrophilic experimental asthma in mice.Allergy. 2019;74(2):294-307.
125. Boudier A, Chanoine S, Accordini S, et al. Data-driven adult asthma
phenotypes based on clinical characteristics are associated with asthma
outcomes twenty years later. Allergy. 2019;74(5):953-963.
126. Ivanova O, Richards LB, Vijverberg SJ, et al. What did we learn
from multiple omics studies in asthma? Allergy.2019;74(11):2129-2145.
127. Su MW, Lin WC, Tsai CH, et al. Childhood asthma clusters reveal
neutrophil-predominant phenotype with distinct gene expression.Allergy. 2018;73(10):2024-2032.
128. Agache I, Beltran J, Akdis C, et al. Efficacy and safety of
treatment with biologicals (benralizumab, dupilumab, mepolizumab,
omalizumab and reslizumab) for severe eosinophilic asthma. A systematic
review for the EAACI Guidelines - recommendations on the use of
biologicals in severe asthma. Allergy. 2020;75(5):1023-1042.
129. Agache I, Rocha C, Beltran J, et al. Efficacy and safety of
treatment with biologicals (benralizumab, dupilumab and omalizumab) for
severe allergic asthma: A systematic review for the EAACI Guidelines -
recommendations on the use of biologicals in severe asthma.Allergy. 2020;75(5):1043-1057.
130. Agache I, Song Y, Rocha C, et al. Efficacy and safety of treatment
with dupilumab for severe asthma: A systematic review of the EAACI
guidelines-Recommendations on the use of biologicals in severe asthma.Allergy. 2020;75(5):1058-1068.
131. Howarth P, Quirce S, Papi A, et al. Eosinophil-derived neurotoxin
and clinical outcomes with mepolizumab in severe eosinophilic asthma.Allergy. 2020.
132. Kuo CS, Pavlidis S, Zhu J, et al. Contribution of airway
eosinophils in airway wall remodeling in asthma: Role of MMP-10 and MET.Allergy. 2019;74(6):1102-1112.
133. Sabogal Pineros YS, Bal SM, Dijkhuis A, et al. Eosinophils capture
viruses, a capacity that is defective in asthma. Allergy.2019;74(10):1898-1909.
134. Tarancon R, Uranga S, Martin C, Aguilo N. Mycobacterium
tuberculosis infection prevents asthma and abrogates eosinophilopoiesis
in an experimental model. Allergy. 2019;74(12):2512-2514.
135. Bagnasco D, Massolo A, Bonavia M, et al. The importance of being
not significant: Blood eosinophils and clinical responses do not
correlate in severe asthma patients treated with mepolizumab in real
life. Allergy. 2020;75(6):1460-1463.
136. Jesenak M, Diamant Z. Blood eosinophils: In quest of a Holy Grail
for personalized asthma treatment with biologicals. Allergy.2020;75(6):1294-1297.
137. Casale TB, Chipps BE, Rosen K, et al. Response to omalizumab using
patient enrichment criteria from trials of novel biologics in asthma.Allergy. 2018;73(2):490-497.
138. Rodrigo-Munoz JM, Canas JA, Sastre B, et al. Asthma diagnosis using
integrated analysis of eosinophil microRNAs. Allergy.2019;74(3):507-517.
139. Granger V, Taille C, Roach D, et al. Circulating neutrophil and
eosinophil extracellular traps are markers of severe asthma.Allergy. 2020;75(3):699-702.
140. Beuraud C, Lombardi V, Luce S, et al. CCR10(+) ILC2s with ILC1-like
properties exhibit a protective function in severe allergic asthma.Allergy. 2019;74(5):933-943.
141. Hoang JA, Mashouri P, Dai R, et al. Extract and component-specific
sensitization patterns in Canadian moderate-to-severe preschool
asthmatics. Allergy. 2019;74(12):2519-2521.
142. Nieto-Fontarigo JJ, Gonzalez-Barcala FJ, Andrade-Bulos LJ, et al.
iTRAQ-based proteomic analysis reveals potential serum biomarkers of
allergic and nonallergic asthma. Allergy. 2020.
143. Pavord ID, Holliday M, Reddel HK, et al. Predictive value of blood
eosinophils and exhaled nitric oxide in adults with mild asthma: a
prespecified subgroup analysis of an open-label, parallel-group,
randomised controlled trial. The Lancet Respiratory Medicine.2020;8(7):671-680.
144. Alvaro-Lozano M, Akdis CA, Akdis M, et al. EAACI Allergen
Immunotherapy User’s Guide. Pediatr Allergy Immunol. 2020;31
Suppl 25(Suppl 25):1-101.
145. Agache I, Lau S, Akdis CA, et al. EAACI Guidelines on Allergen
Immunotherapy: House dust mite-driven allergic asthma. Allergy.2019;74(5):855-873.
146. Farraia M, Cavaleiro Rufo J, Paciência I, et al. Human volatilome
analysis using eNose to assess uncontrolled asthma in a clinical
setting. Allergy. 2020;75(7):1630-1639.
147. Abdel-Aziz MI, de Vries R, Lammers A, et al. Cross-sectional
biomarker comparisons in asthma monitoring using a longitudinal design:
The eNose premise. Allergy. 2020;doi: 10.1111/all.14354. Online
ahead of print.
148. Cavaleiro Rufo J, Paciencia I, Mendes FC, et al. Exhaled breath
condensate volatilome allows sensitive diagnosis of persistent asthma.Allergy. 2019;74(3):527-534.
149. Bousquet J, Hellings PW, Agache I, et al. Allergic Rhinitis and its
Impact on Asthma (ARIA) Phase 4 (2018): Change management in allergic
rhinitis and asthma multimorbidity using mobile technology. J
Allergy Clin Immunol. 2019;143(3):864-879.
150. Bédard A, Antó JM, Fonseca JA, et al. Correlation between work
impairment, scores of rhinitis severity and asthma using the MASK-air(®)
App. Allergy. 2020;75(7):1672-1688.
151. Bousquet J, Arnavielhe S, Bedbrook A, et al. The Allergic Rhinitis
and its Impact on Asthma (ARIA) score of allergic rhinitis using mobile
technology correlates with quality of life: The MASK study.Allergy. 2018;73(2):505-510.
152. Bousquet J, Agache I, Aliberti MR, et al. Transfer of innovation on
allergic rhinitis and asthma multimorbidity in the elderly (MACVIA-ARIA)
- EIP on AHA Twinning Reference Site (GARD research demonstration
project). Allergy. 2018;73(1):77-92.
153. Peters MC, Wenzel SE. Intersection of biology and therapeutics:
type 2 targeted therapeutics for adult asthma. Lancet.2020;395(10221):371-383.
154. Fahy JV. Type 2 inflammation in asthma–present in most, absent
in many. Nat Rev Immunol. 2015;15(1):57-65.
155. Akdis CA, Arkwright PD, Brüggen MC, et al. Type 2 immunity in the
skin and lungs. Allergy. 2020;75(7):1582-1605.
156. McDowell PJ, Heaney LG. Different endotypes and phenotypes drive
the heterogeneity in severe asthma. Allergy. 2020;75(2):302-310.
157. Ho T, Al-Selahi E, Mukherjee M, et al. Sputum and serum
immunoglobulins in adult asthmatics with recurrent respiratory tract
infections. Allergy. 2020.
158. Fieten KB, Rijssenbeek-Nouwens LH, Hashimoto S, Bel EH, Weersink
EJ. Less exacerbations and sustained asthma control 12 months after high
altitude climate treatment for severe asthma. Allergy.2019;74(3):628-630.
159. Fieten KB, Zijlstra WT, van Os-Medendorp H, et al. Comparing high
altitude treatment with current best care in Dutch children with
moderate to severe atopic dermatitis (and asthma): study protocol for a
pragmatic randomized controlled trial (DAVOS trial). Trials.2014;15:94.
160. Boonpiyathad T, Capova G, Duchna HW, et al. Impact of high-altitude
therapy on type-2 immune responses in asthma patients. Allergy.2020;75(1):84-94.
161. Seys SF, Quirce S, Agache I, et al. Severe asthma: Entering an era
of new concepts and emerging therapies: Highlights of the 4th
international severe asthma forum, Madrid, 2018. Allergy.2019;74(11):2244-2248.
162. Eyerich S, Metz M, Bossios A, Eyerich K. New biological treatments
for asthma and skin allergies. Allergy. 2020;75(3):546-560.
163. Voorham J, Xu X, Price DB, et al. Healthcare resource utilization
and costs associated with incremental systemic corticosteroid exposure
in asthma. Allergy. 2019;74(2):273-283.
164. Papadopoulos NG, Barnes P, Canonica GW, et al. The evolving
algorithm of biological selection in severe asthma. Allergy.2020;75(7):1555-1563.
165. Israel E, Reddel HK. Severe and Difficult-to-Treat Asthma in
Adults. The New England journal of medicine.2017;377(10):965-976.
166. Chapman KR, Albers FC, Chipps B, et al. The clinical benefit of
mepolizumab replacing omalizumab in uncontrolled severe eosinophilic
asthma. Allergy. 2019;74(9):1716-1726.
167. Mukherjee M, Bakakos P, Loukides S. New paradigm in asthma
management: Switching between biologics! Allergy.2020;75(4):743-745.
168. Deschildre A, Roussel J, Drumez E, et al. Omalizumab
discontinuation in children with severe allergic asthma: An
observational real-life study. Allergy. 2019;74(5):999-1003.
169. Mathur SK, Modena BD, Coumou H, Barker P, Kreindler JL, Zangrilli
JG. Postbronchodilator lung function improvements with benralizumab for
patients with severe asthma. Allergy. 2020;75(6):1507-1510.
170. Antonicelli L, Tontini C, Marchionni A, Lucchetti B, Garritani MS,
Bilò MB. Forced oscillation technique as method to document and monitor
the efficacy of mepolizumab in treating severe eosinophilic asthma.Allergy. 2020;75(2):433-436.
171. Agache I, Akdis C, Akdis M, et al. EAACI Biologicals
Guidelines-Recommendations for severe asthma. Allergy. 2020.
172. Lombardi C, Passalacqua G, Bagnasco D. Severe asthma, biologicals,
and auto-injection: Yes, no, may be! Allergy. 2020;75(2):444-445.
173. Sokolowska M, Rovati GE, Diamant Z, et al. Current perspective on
eicosanoids in asthma and allergic diseases - EAACI Task Force consensus
report, part I. Allergy. 2020.
174. Maun HR, Jackman JK, Choy DF, et al. An Allosteric Anti-tryptase
Antibody for the Treatment of Mast Cell-Mediated Severe Asthma.Cell. 2020;180(2):406.
175. Kere M, Gruzieva O, Ullemar V, et al. Effects of inhaled
corticosteroids on DNA methylation in peripheral blood cells in children
with asthma. Allergy. 2020;75(3):688-691.
176. Schmitt J, Wüstenberg E, Küster D, Mücke V, Serup-Hansen N, Tesch
F. The moderating role of allergy immunotherapy in asthma progression:
Results of a population-based cohort study. Allergy.2020;75(3):596-602.
177. Boonpiyathad T, Pradubpongsa P, Mitthamsiri W, Satitsuksanoa P,
Jacquet A, Sangasapaviliya A. Allergen-specific immunotherapy boosts
allergen-specific IgD production in house dust mite-sensitized asthmatic
patients. Allergy. 2020;75(6):1457-1460.
178. Devillier P, Molimard M, Ansolabehere X, et al. Immunotherapy with
grass pollen tablets reduces medication dispensing for allergic rhinitis
and asthma: A retrospective database study in France. Allergy.2019;74(7):1317-1326.
179. Wahn U, Bachert C, Heinrich J, Richter H, Zielen S. Real-world
benefits of allergen immunotherapy for birch pollen-associated allergic
rhinitis and asthma. Allergy. 2019;74(3):594-604.
180. Zielen S, Devillier P, Heinrich J, Richter H, Wahn U. Sublingual
immunotherapy provides long-term relief in allergic rhinitis and reduces
the risk of asthma: A retrospective, real-world database analysis.Allergy. 2018;73(1):165-177.
181. Mösges R, Bachert C, Panzner P, et al. Short course of grass
allergen peptides immunotherapy over 3 weeks reduces seasonal symptoms
in allergic rhinoconjunctivitis with/without asthma: A randomized,
multicenter, double-blind, placebo-controlled trial. Allergy.2018;73(9):1842-1850.
182. Asaria M, Dhami S, van Ree R, et al. Health economic analysis of
allergen immunotherapy for the management of allergic rhinitis, asthma,
food allergy and venom allergy: A systematic overview. Allergy.2018;73(2):269-283.
183. Hesse L, van Ieperen N, Habraken C, et al. Subcutaneous
immunotherapy with purified Der p1 and 2 suppresses type 2 immunity in a
murine asthma model. Allergy. 2018;73(4):862-874.
184. Crossman-Barnes CJ, Peel A, Fong-Soe-Khioe R, Sach T, Wilson A,
Barton G. Economic evidence for nonpharmacological asthma management
interventions: A systematic review. Allergy.2018;73(6):1182-1195.
185. Bousquet J, Jutel M, Akdis CA, et al. ARIA-EAACI statement on
Asthma and COVID-19 (June 2, 2020). Allergy. 2020.
186. Avdeev S, Moiseev S, Brovko M, et al. Low prevalence of bronchial
asthma and chronic obstructive lung disease among intensive care unit
patients with COVID-19. Allergy. 2020.
187. Zhang JJ, Dong X, Cao YY, et al. Clinical characteristics of 140
patients infected with SARS-CoV-2 in Wuhan, China. Allergy.2020;75(7):1730-1741.
188. Carli G, Cecchi L, Stebbing J, Parronchi P, Farsi A. Is asthma
protective against COVID-19? Allergy. 2020.
189. Johnston SL. Asthma and COVID-19: Is asthma a risk factor for
severe outcomes? Allergy. 2020;75(7):1543-1545.
190. Beaney T, Salman D, Samee T, Mak V. Assessment and management of
adults with asthma during the covid-19 pandemic. BMJ.2020;369:m2092.
191. Zhu Z, Hasegawa K, Ma B, Fujiogi M, Camargo CA, Liang L.
Association of asthma and its genetic predisposition with the risk of
severe COVID-19. J Allergy Clin Immunol.2020;146(2):327-329.e324.
192. Licari A, Votto M, Brambilla I, et al. Allergy and asthma in
children and adolescents during the COVID outbreak: What we know and how
we could prevent allergy and asthma flares. Allergy. 2020.
193. Sokolowska M, Lukasik Z, Agache I, et al. Immunology of COVID-19:
mechanisms, clinical outcome, diagnostics and perspectives - a report of
the European Academy of Allergy and Clinical Immunology (EAACI).Allergy. 2020.
194. Azkur AK, Akdis M, Azkur D, et al. Immune response to SARS-CoV-2
and mechanisms of immunopathological changes in COVID-19.Allergy. 2020;75(7):1564-1581.
195. Riggioni C, Comberiati P, Giovannini M, et al. A compendium
answering 150 questions on COVID-19 and SARS-CoV-2. Allergy.2020.
196. Radzikowska U, Ding M, Tan G, et al. Distribution of ACE2, CD147,
CD26 and other SARS-CoV-2 associated molecules in tissues and immune
cells in health and in asthma, COPD, obesity, hypertension, and COVID-19
risk factors. Allergy. 2020.
197. Wang JY, Pawankar R, Tsai HJ, Wu SL, Kuo WS. COVID-19 and Asthma,
the Good or the Bad? Allergy. 2020.
198. Leonardi A, Fauquert JL, Doan S, et al. Managing ocular allergy in
the time of COVID-19. Allergy. 2020.
199. Vultaggio A, Agache I, Akdis CA, et al. Considerations on
Biologicals for Patients with allergic disease in times of the COVID-19
pandemic: an EAACI Statement. Allergy. 2020.
200. Pfaar O, Klimek L, Jutel M, et al. COVID-19 pandemic: Practical
considerations on the organization of an allergy clinic - an EAACI/ARIA
Position Paper. Allergy. 2020.
201. Klimek L, Jutel M, Akdis C, et al. Handling of allergen
immunotherapy in the COVID-19 pandemic: An ARIA-EAACI statement.Allergy. 2020;75(7):1546-1554.
202. Bousquet J, Akdis C, Jutel M, et al. Intranasal corticosteroids in
allergic rhinitis in COVID-19 infected patients: An ARIA-EAACI
statement. Allergy. 2020.
203. Klimek L, Hagemann J, Alali A, et al. Telemedicine allows
quantitative measuring of olfactory dysfunction in COVID-19.Allergy. 2020.
204. Akbarshahi H, Menzel M, Ramu S, Mahmutovic Persson I, Bjermer L,
Uller L. House dust mite impairs antiviral response in asthma
exacerbation models through its effects on TLR3. Allergy.2018;73(5):1053-1063.
205. Lommatzsch M, Stoll P, Virchow JC. COVID-19 in a patient with
severe asthma treated with Omalizumab. Allergy. 2020.
206. Bilò MB, Pravettoni V, Mauro M, Bonadonna P. Treating venom allergy
during COVID-19 pandemic. Allergy. 2020.